A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Date Added
November 3rd, 2020
PRO Number
Pro00104644
Researcher
Carol Sherman

List of Studies


Keywords
Cancer, Cancer/Lung
Summary

This study is for patients that have been diagnosed with Non-Squamous Non-Small-Cell Lung Carcinoma (NSCLC). The purpose of this study is to compare the two investigational treatments (cabozantinib alone to using cabozantinib plus the usual treatment nivolumab) to the current standard of care second line therapy. The study drugs involved are cabozanitib alone and cabozantinib plus nivolumab. Participants can expect to be on this study for up to 3 years.

Institution
MUSC
Recruitment Contact
Amanda Kelley, RN
864-725-7125
amanda.kelley@selfregional.org



-- OR --